ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.

MD, PhD, FERS

Klaus Rabe +2 more

On demand materials

Pulmonology

78 min

expert video

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

Pulmonology

30 min

expert video

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

ERS 2024 | Can Biologics Affect Airway Remodeling?

Pulmonology

20 min

expert video

ERS 2024 | Can Biologics Affect Airway Remodeling?

Pulmonology

12 min

expert video

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

Learning objectives

Understand how type 2 inflammation drives the manifestations of airway remodeling found in severe asthma
Identify the clinical consequences of airway remodeling in severe asthma
Explore the role of biologic therapy in mitigating the effects of airway remodeling on severe asthma patients

About these experts

Pulmonology

MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

Pulmonology

MD, PhD

Celeste Porsbjerg

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

Pulmonology

MD, MPH

Mario Castro

Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, University of Kansas School of Medicine

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BelgiumChange country/region